initial public offerings (IPOs) trading on American exchanges

Monday, March 2, 2015

TRACON Pharmaceuticals (TCON) began trading on the NASDAQ on 30 January 2015


TRACON Pharmaceuticals, Inc. (TRACON) is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of targeted therapeutics for cancer, age-related macular degeneration(AMD) and fibrotic diseases. The Company is engaged in the field of endoglin biology and develops antibodies that bind to the endoglin receptor. The Company’s lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF), pathway. Its other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.


8910 University Center Ln Ste 700
SAN DIEGO, CA 92122-1060
United States

Key stats and ratios

Q3 (Sep '14)2013
Net profit margin-169.37%-
Operating margin-150.31%-
EBITD margin--
Return on average assets-27.86%-306.48%
Return on average equity--

No comments:

Post a Comment